Antipsychotic Trials in Schizophrenia: The CATIE Project

by Edited by T. Scott Stroup , Jeffrey A. Lieberman

• ISBN13: 9780521895330
• ISBN10: 0521895332
• Edition: 1st
• Format: Hardcover
• Copyright: 2010-05-24
• Publisher: Cambridge University Press

Summary

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.

Author Biography

T. Scott stroup is Director of the Program for Intervention Effectiveness Research in the Department of Psychiatry, Columbia University, College of Physicians and Surgeons, and the New York State Psychiatric Institute, New York, USA.
Jeffrey A. Lieberman is Chairman, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, Director, New York State Psychiatric Institute, Director, Lieber Center for Schizophrenia Research, and Psychiatrist-in-chief at New York Presbyterian Hospital and Columbia University Medical Center, New York, USA.

Table of Contents

List of contributors	p. ix
Acknowledgments	p. xi
Introduction	p. xiii
Study design and protocol development process	p. 1
Statistical considerations	p. 22
Effectiveness and efficacy: staying on treatment and symptom reduction	p. 39
Cost-effectiveness and cost-benefit analysis	p. 57
Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study	p. 80
Neurocognition	p. 97
Vocational outcomes	p. 120
Family outcomes	p. 133
Extrapyramidal side effects	p. 156
Metabolic side effects and risk of cardiovascular disease	p. 173
Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome	p. 189
Violence in schizophrenia: prevalence, correlates, and treatment effectiveness	p. 207
Genetic investigations in the Catie sample	p. 237
Human subjects considerations	p. 255
Population pharmacokinetics of antipsychotics	p. 267
Implications for research design and study implementation	p. 281
Conclusion and implications for practice and policy	p. 288
Index	p. 307
Table of Contents provided by Ingram. All Rights Reserved.